1. Home
  2. TISI vs IMA Comparison

TISI vs IMA Comparison

Compare TISI & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Team Inc.

TISI

Team Inc.

N/A

Current Price

$16.70

Market Cap

76.3M

ML Signal

N/A

IMA

ImageneBio Inc.

N/A

Current Price

$5.97

Market Cap

66.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TISI
IMA
Founded
1973
2019
Country
United States
United States
Employees
6800
17
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.3M
66.3M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
TISI
IMA
Price
$16.70
$5.97
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
$16.00
AVG Volume (30 Days)
3.2K
8.4K
Earning Date
05-12-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$896,483,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.19
N/A
52 Week Low
$12.34
$3.94
52 Week High
$19.99
$17.50

Technical Indicators

Market Signals
Indicator
TISI
IMA
Relative Strength Index (RSI) 53.02 47.05
Support Level $16.62 $5.36
Resistance Level $17.10 $6.13
Average True Range (ATR) 0.65 0.31
MACD -0.03 -0.03
Stochastic Oscillator 52.17 37.76

Price Performance

Historical Comparison
TISI
IMA

About TISI Team Inc.

Team Inc provides specialty industrial services, including inspection, engineering assessment, and mechanical repair and remediation required in maintaining high-temperature and high-pressure piping systems and vessels utilized in refining, petrochemicals, and others. The company operates in two segments, Inspection and Heat Treating and Mechanical Services. The Inspection and Heat Treating segment, which generates maximum revenue, provides conventional and non-destructive testing services for the process, pipeline, and power sectors, pipeline integrity management services, and field heat treating services, as well as associated engineering and condition assessment services. Geographically, the company derives its key revenue from the United States, followed by other countries, and Canada.

About IMA ImageneBio Inc.

ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.

Share on Social Networks: